A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

NCT07471048 | Recruiting

• 1 other identifier: PS21-14773
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate whether Viv, a consumer-grade dietary supplement derived from the Magnolia officinalis plant, has an effect on biomarkers of immune activity in adults with psoriasis. To address this question, this trial will compare Viv to a placebo (a look-alike substance that contains no drug). Participants will:

• Take Viv or a placebo every day for 3 months.
• Complete electronic questionnaires about their quality of life and psoriasis symptoms at the beginning of the study and again at 1 months and 3 months.
• Be provided with at home blood collection kits, which they will use to collect blood at the beginning of the study and again at 1 months and 3 months. Researchers will analyze these blood samples to measure the levels of specific inflammatory proteins and evaluate how they change over the course of the study in the participants taking Viv compared to those taking placebo.

Conditions

Psoriasis

Outcome Measures

Primary Outcomes (1)

• Relative change in plasma Beta defensin 2 from baseline

  Change in plasma Beta defensin 2 levels between placebo and study product group at 4 weeks and 12 weeks relative to baseline as measured by ELISA

  From baseline to the end of study product/placebo use at 12 weeks

Secondary Outcomes (4)

• Exploratory analyses of serum proteomics

  Baseline to end of study product/placebo use at 12 weeks

• Exploratory analysis of circulating immune cells

  Baseline to end of study product/placebo use at 12 weeks

• Quality of life assessment

  Baseline to end of study product/placebo use at 12 weeks

• Self reported psoriasis symptoms

  Baseline to end of study product/placebo use at 12 weeks

Study Arms (2)

Viv

EXPERIMENTAL

Magnolia officinalis study arm

Dietary Supplement: Oral supplement containing 200mg Magnolia officinalis bark extract

Placebo

PLACEBO COMPARATOR

Placebo control study arm

Dietary Supplement: Placebo

Interventions

Oral supplement containing 200mg Magnolia officinalis bark extract DIETARY_SUPPLEMENT

Viv is a consumer grade oral supplement containing 200mg Magnolia officinalis bark extract encapsulated in a hypromellose capsule.

Viv

Placebo DIETARY_SUPPLEMENT

Oral hypromellose capsule with all inactive ingredients but lacking the Magnolia officinalis bark extract

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male of female, aged 18 years or older at time of consent.
• Diagnosis of stable psoriasis affecting for at least 6 months confirmed by a dermatologist.

You may not qualify if:

• Able to read and understand English.
• Able to read, understand, and provide informed consent.
• Able to use a personal smartphone device and download Chloe by People Science.
• Able to receive shipment of the product at an address within the United States.
• Able to adhere to study protocol (e.g., willing to collect and ship blood samples)
• Any potential participants who:
• Do not have a personal smartphone, internet access, or unwilling to download Chloe.
• Prior treatment with any systemic non-biologic immunosuppressive agents (e.g., methotrexate, cyclosporine, azathioprine) within 8 weeks prior to randomization.
• Prior treatment with any systemic biologic therapies (e.g., guselkumab, risankizumab, ustekinumab, secukinumab, brodalumab, infliximab, adalimumab, golimumab, etanercept) within 6 months prior to randomization
• Prior treatment with any other systemic investigational drugs within 6 months prior to randomization.
• Other Illnesses or Conditions: Participants who have the following comorbidities or gastrointestinal illnesses are excluded:
• Currently pregnant, planning to become pregnant in the next 3 months, or breastfeeding
• Any underlying medical conditions or comorbidities that may confound the assessment of digestive symptoms or the evaluation of the study outcomes.
• Have a significant illness, disease or condition which, in the opinion of the principal investigator, may impact their ability to participate in the study or impact the study outcomes.
• Known hypersensitivity or previous allergic reaction to magnolia, rice or hypromellose.

Sponsors & Collaborators

• Sirt3 LLC: lead
• People Science, Inc.: collaborator

Study Sites (1)

Decentralized Study Coordinating Center

Englewood, New Jersey, 07631, United States

RECRUITING

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Adeeb Rahman, PhD

CONTACT

2013596845; clinicaltrial@takeviv.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of Translational Research

Study Record Dates

• First Submitted: March 10, 2026
• First Posted: March 13, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): September 1, 2029
• Last Updated: March 13, 2026

Record last verified: 2026-03

Locations

US (1)